Compounded GLP-1s are being phased out: what that actually means

What did @gudgelaesthetics actually say?

The creator pitched cagrilintide as a backup option now that compounded GLP-1s face regulatory pressure. They described it as "a long-acting amylin analog" that works on "the amylin pathway and the calcitonin receptors," called it a "dual agonist for appetite suppression and glucose control," and said clinical trials show "10% body weight reduction after 26 weeks." They also flagged nausea and constipation as expected side effects and noted ongoing trials combining cagrilintide with semaglutide. The framing was measured compared to typical weight-loss content.

The worry is the implied pivot: cagrilintide is positioned as something a clinic can simply stock and inject, available "for as long as we can foresee." That sidesteps a significant fact: cagrilintide is not FDA-approved as a standalone drug. Patients watching this may not register that distinction.

Does the science back this up?

Mostly, but with important caveats. The mechanistic description is accurate. Cagrilintide is a long-acting amylin analog that acts on amylin receptors and calcitonin receptors. Amylin is a pancreatic hormone that slows gastric emptying and suppresses glucagon, and synthetic analogs exploit both receptor types. That part checks out.

The 10% weight loss figure at 26 weeks is real but comes from a specific dose range. The SCALE-like phase 2 trial (Enebo et al., 2021, The Lancet) tested cagrilintide at doses from 0.3 mg to 4.5 mg alongside diet and exercise in adults with obesity. The 4.5 mg dose produced a mean weight reduction of about 10.8% at 26 weeks. Lower doses produced less. The creator cited 10% without mentioning that the result is dose-dependent and that these were phase 2 findings, not the larger phase 3 trials that regulators require for approval decisions.

The CagriSema combination data the creator references is also real. Phase 2 results published by Lau et al. (2023, The Lancet) showed CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) producing roughly 15% weight loss at 32 weeks, which is meaningfully better than either drug alone in that trial population. Those trials are ongoing at larger scale.

What did they get wrong (or right)?

They got the pharmacology right. The dual-receptor mechanism description is accurate, and flagging GI side effects like nausea and constipation is appropriate and honest. Credit where it is due.

What they got wrong, or at least incomplete: cagrilintide has no standalone FDA approval as of 2024. It is an investigational compound. Compounded versions of unapproved drugs sit in a murky regulatory space that is distinct from compounded versions of approved drugs like semaglutide. Describing it as something a clinic can simply "order" and stock "for as long as we can foresee" is optimistic in a way that could mislead patients about its regulatory status and quality-control oversight.

Calling it a "dual agonist" is also slightly imprecise. Cagrilintide is a single molecule acting on two related receptor types (amylin receptor complexes and calcitonin receptors), which overlap significantly in structure. The term dual agonist is not wrong, but it implies a mechanism analogous to tirzepatide's GIP-GLP-1 dual agonism, which is a different situation. That conflation could leave viewers with a skewed impression of how the drug works.

What should you actually know?

Cagrilintide is a legitimate investigational compound with real phase 2 evidence behind it. It is not a fringe peptide. Novo Nordisk is actively developing it, and the CagriSema combination is in a large phase 3 trial called REDEFINE. If those results hold up, it could eventually become an approved treatment option.

But "eventually" is doing a lot of work here. As of now, no version of cagrilintide is FDA-approved for any indication. Any cagrilintide being offered at a medspa or aesthetics clinic is a compounded product sourced outside standard pharmaceutical supply chains. Patients should ask pointed questions: Where is the compound sourced? What quality testing has been done on that specific batch? What happens if a side effect occurs that requires a documented treatment protocol?

The pivot framing in this video, while understandable from a business standpoint given the regulatory pressure on compounded semaglutide, should not be interpreted as clinical equivalence. Switching from a compounded version of an FDA-approved drug to a compounded version of an unapproved investigational compound is a meaningful step, not a lateral move.

Bottom line

The science cited here is real and the mechanistic explanation is largely accurate. But the regulatory framing is missing, and that gap matters for patients making decisions. Ask your provider specifically about approval status and compound sourcing before agreeing to any injection of cagrilintide.